A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Breast Cancer; Salivary Gland Cancer; Esophageal Cancer; Urothelial Carcinoma; Gastroesophageal Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Non-small Cell Lung Cancer; HER-2 Protein Overexpression; Pancreatic Cancer; Colorectal Cancer

Treatments: Drug: Zanidatamab

Study type: Interventional

Funder types: Industry

Identifiers

NCT06695845

JZP598-206

2024-516551-41-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Is at least 18 years of age inclusive at the time of signing the informed consent

2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.

3. HER2 overexpression (IHC 3+) via Immunohistochemistry (IHC).

4. All participants must have adequate tumor sample for submission to allow central HER2 testing.

5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Has a life expectancy of at least 3 months, in the opinion of the investigator.

8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met:

   1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.
   2. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.
   3. Recovery to no more than Grade 1 or baseline from any acute toxicity associated with the treatment.

9. Adequate organ functions.

10. Females of childbearing potential must have a negative pregnancy test result.

11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.

Exclusion criteria

1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis.
2. Has uncontrolled or significant cardiovascular disease
3. Has ongoing toxicity related to prior cancer therapy
4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.
5. Has known Human Immunodeficiency Virus (HIV) infection.
6. Has active hepatitis B or C infection.
7. Has an active severe acute respiratory syndrome coronavirus 2 infection.
8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab.
9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site.
10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.
11. Prior treatment with HER2-targeted therapy (Cohort 1 only).
12. Has a history of trauma or major surgery
13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to enrollment.
14. Was treated in a prior clinical study of zanidatamab or received zanidatamab at any time prior to the current study.
15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations.
16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.
17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

Zanidatamab treatment arm

Experimental group

Description:

Eligible participants receiving zanidatamab treatment

Treatment:

Drug: Zanidatamab